
0:00
22:37
On January 6, 2023, the US FDA approved lecanemab for the treatment of Alzheimer’s disease (AD), making history as the first ever treatment to significantly slow cognitive decline. Despite the excitement surrounding this breakthrough approval, concerns remain regarding the extent of lecanemab's clinical benefit and the risks involved with its use. In this episode, experts delve review the evidence, reflecting on the performance of lecanemab and future directions for anti-amyloid therapies.
Flere episoder fra "VJDementia Podcast"



Gå ikke glip af nogen episoder af “VJDementia Podcast” - abonnér på podcasten med gratisapp GetPodcast.








